NCT01780454View on ClinicalTrials.gov

Renal Allograft Tolerance Through Mixed Chimerism

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2020

Conditions
End Stage Renal Disease
Interventions
DRUG

MEDI-507

T-Cell Depleting Agent

DRUG

Rituximab

B-Cell Depleting Agent

RADIATION

Total Body Irradiation

Bone Marrow Depletion

RADIATION

Thymic Irradiation

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT01780454 - Renal Allograft Tolerance Through Mixed Chimerism | Biotech Hunter | Biotech Hunter